BRIC Clinical Trials Report: Opportunities and Challenges

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights click here. By clicking the "Download button" you agree to the terms of our Privacy Policy.

India is primed to become a hub for clinical research and clinical outsourcing activities. In a recent global study by Pharma IQ entitled “BRIC Clinical Trials: Opportunities and Challenges”, over half of the survey participants 53.5 % identified India as the BRIC country with the greatest opportunities for clinical trials.

With higher attrition of potential candidates in various phases of drug development and a lack of new drugs, the global clinical trials landscape has changed in recent years. As accessibility, visibility and data quality have increased in the BRIC nations, conducting carrying out clinical trials in Brazil, China, India and Russia has become a much more attractive global proposition. The large patient pools being cited by the survey respondents as the main reason for investing and outsourcing clinical activities to these regions.

In this report we explore the opportunities and challenges BRIC counties currently present for the global clinical trials market.